Research News and Research

RSS

Abortion continues to snag health reform legislation, divide lawmakers

The divisive issue of abortions, a lingering hurdle to health reform legislation, is plaguing both House and Senate Democratic leaders, the Los Angeles Times reports. "The delays in both houses reflect the fact that even though Democrats hold solid majorities, significant divisions exist below the surface.

4 Nov 2009

AMFm subsidized malaria drugs to be delivered soon

Subsidized artemisinin-based combination therapies (ACTs) under the Affordable Medicines Facility - malaria (AMFm) program will be available in select countries "in two week's time," SABC News reports. The announcement came Monday at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya.

4 Nov 2009

Possible cure for Parkinson's disease

Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others.

4 Nov 2009

Veterans Administration leads in e-health exchange, too

The Veterans Health Administration was at the avant-garde of electronic medical records in the 1980s, and more recently, it's blazed the trail for exchanging health information between providers, the Lawrence (Kan.) Journal-World reports in the third of a 3-part series on EMRs.

4 Nov 2009

Health bills don't go far enough in cutting costs, experts say

"Democrats in Congress are embracing the spirit of President Obama's call to slow the runaway rise of health-care costs but are shying away from some of the most aggressive techniques for achieving that," The Washington Post reports. "Instead of revolutionizing how care is delivered and paid for, experts say, the legislation being shaped takes a cautious approach to reining in costs."

4 Nov 2009

Foamix' emollient foam platform awarded Mexican patent

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled "Cosmetic and Pharmaceutical Foam." The patent covers Foamix's vehicles, compositions and cosmetic and pharmaceutical uses thereof based on the company's Emollient Foam technology platform.

4 Nov 2009

MRG's new report on the European markets for small-joint reconstructive implants

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European market for small-joint reconstructive implants will double by 2014, reaching almost $360 million.

4 Nov 2009

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market -- driven by the launch of several targeted agents over the next few years -- will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

4 Nov 2009

Conflicts of interest examined between doctors and medical industry, AARP and reform

Health care reform bills include provisions to examine the financial relationships between doctors and the medical industry while some are questioning the AARP's role in reform.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Watson Pharmaceuticals announces third quarter 2009 financial results

Watson Pharmaceuticals, Inc. today reported net income of $63.0 million, or $0.55 per diluted share for the third quarter ended September 30, 2009. Excluding special items as detailed in the reconciliation table below, adjusted net income for the third quarter was $76.1 million, or $0.66 per diluted share, an increase of $22.1 million or 41 percent over the adjusted net income for the third quarter ended September 30, 2008. As detailed in the attached reconciliation table, adjusted EBITDA for the third quarter was $178.4 million.

4 Nov 2009

Third quarter 2009 financial results announced by Affymax

Affymax, Inc. today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008.

4 Nov 2009

Garmin reports financial results for the third quarter of 2009

Garmin Ltd. today announced third quarter results for the period ended September 26, 2009.

From Garmin 4 Nov 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007.

4 Nov 2009

Osiris Therapeutics reports financial results for the third quarter of 2009

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009.

4 Nov 2009

New pediatric simulation center launched by Texas Children's Hospital

Texas Children's Hospital opened the doors of its brand new Simulation Center today, where healthcare teams will be trained in the management of rare, complex, and complicated patient care through a simulated clinical environment. The facility is the only center of its kind in Texas, and one of the largest among the twelve pediatric simulation centers in the United States.

4 Nov 2009

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2009.

4 Nov 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.

4 Nov 2009

Cipher Pharmaceuticals announces financial results for the third quarter of 2009

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2009.

4 Nov 2009

Cosmeceutical industry records increased growth

The global market for cosmeceuticals (cosmetics offering health benefits) is growing nearly twice as fast as the overall cosmetics and toiletries market. However, in order to sustain such rapid growth, manufacturers and brand owners must fill a relentless demand for new ingredient concepts in a context of changing government regulations, market dynamics and cultural trends.

4 Nov 2009